Xenon Pharmaceuticals Inc.
NASDAQ:XENEBiotechnology
-$0.29 today
- Market cap
- $3.71B
- Beta
- 0.63
- P/E (TTM)
- -12.1
- EPS (TTM)
- -$4.39
Volume 1.30M
Average 1.16M
XENE Net Margin
Net income as a percentage of revenue, showing how much of each sales dollar becomes profit.
Xenon Pharmaceuticals Inc.NASDAQ: XENE
Net Margin · Q3 FY2026 · quarter ended Sep 2026
Net margin not reported for Q3 FY2026
Over 3 fiscal years it narrowed by 3283.2 pp.
What to watch
Whether net margin reaches the consensus estimate from 7 analysts of -25398.7% for the fiscal year ending Dec 2026, down from -4612.1% in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterSep 2026
- —— QoQ
- Last fiscal yearDec 2025
- -4612.1%— YoY
- LTMSep 2026
- —— YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | — | — | — |
| 1 year | — | -20786.6 pp | — |
| 3 years | -3283.2 pp | +4488.9 pp | +7772.1 pp |
| 5 years | +4636.1 pp | — | |
| 10 years | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Net Margin history
Percent of revenue · from the income statement
- Latest · FY2025
- -4612.1%
- Year-over-year change
- —
| Period | Period end | Net Margin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | -4612.1% | — |
| FY2024 | 2024-12-31 | — | — |
| FY2023 | 2023-12-31 | — | — |
| FY2022 | 2022-12-31 | -1328.9% | -901.1pp |
| FY2021 | 2021-12-31 | -427.8% | — |
Net Margin vs competitors
How XENE compares with its peers on the latest reported figures
- XENE's FY2025 net margin of -4612.1% is the 7th highest of the 8 companies compared; the peer median is -13.2%.
- Over three fiscal years its change of -3283.2 pp compares with a peer median of +6.4 pp.
| Company | Period | LTM level | YoY | 3-year change |
|---|---|---|---|---|
| LTM Sep 2026 | 30.1% | +5.2 pp | +78.2 pp | |
| LTM Sep 2026 | 19.0% | +3.0 pp | +6.4 pp | |
| LTM Sep 2026 | 4.4% | +13.2 pp | -2.2 pp | |
| LTM Jun 2026 | -13.2% | -22.9 pp | -14.5 pp | |
| LTM Jun 2026 | -24.7% | +25.2 pp | +345.3 pp | |
RAPPRapport Therapeutics, Inc. Common Stock | LTM Mar 2026 | -536.4% | — | — |
| FY2025 | -4612.1% | — | -3283.2 pp | |
| LTM Jun 2026 | -14191.2% | — | — | |
| FY2025 | — | — | — | |
| FY2025 | — | — | — | |
NMRANeumora Therapeutics, Inc. Common Stock | FY2025 | — | — | — |
| Peer median (excluding XENE) | -13.2% | +5.2 pp | +6.4 pp | |
Competitors are the stored peer set for XENE. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 18.44M | 9.43M | 0 | 0 | 7.5M |
| Cost of Revenue | 0 | 0 | 167.51M | 2.56M | 2.54M |
| Gross Profit | 18.44M | 9.43M | (167.51M) | (2.56M) | 4.96M |
| Gross Margin | 100.0% | 100.0% | — | — | 66.1% |
| Research & Development | 75.46M | 105.77M | 167.51M | 210.39M | 300.94M |
| Selling, General & Admin | 21.97M | 32.81M | 46.54M | 68.9M | 79.63M |
| Operating Expenses | 97.43M | 138.58M | 46.54M | 276.74M | 378.03M |
| Depreciation & Amortization | 906K | 1.41M | 3.54M | 2.56M | 2.54M |
| EBITDA | (78.09M) | (127.74M) | (210.51M) | (235.86M) | (342.35M) |
| EBITDA Margin | -423.5% | -1354.0% | — | — | -4564.7% |
| Operating Income | (78.99M) | (129.14M) | (214.05M) | (279.3M) | (373.07M) |
| Operating Margin | -428.4% | -1368.9% | — | — | -4974.3% |
| Interest Income | 466K | 8.71M | 27.62M | 41.94M | 26.83M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | 105K | 3.89M | 31.37M | 40.88M | 28.18M |
| Income Before Tax | (78.89M) | (125.26M) | (182.69M) | (238.42M) | (344.89M) |
| Pre-Tax Margin | -427.9% | -1327.7% | — | — | -4598.6% |
| Income Tax Expense | (6K) | 118K | (292K) | (4.09M) | 1.02M |
| Net Income | (78.88M) | (125.37M) | (182.39M) | (234.33M) | (345.91M) |
| Net Margin | -427.8% | -1328.9% | — | — | -4612.1% |
| EPS (Basic) | (1.77) | (2.06) | (2.73) | (3.01) | (4.36) |
| EPS (Diluted) | (1.77) | (2.06) | (2.73) | (3.01) | (4.36) |
| Weighted Avg Shares | 43.63M | 60.54M | 66.89M | 77.89M | 79.25M |
| Weighted Avg Shares (Diluted) | 43.63M | 60.54M | 66.89M | 77.89M | 79.25M |
Xenon Pharmaceuticals Inc.
NASDAQ:XENE
Intrinsic Alpha fair value
Locked
Current Price
$37.75
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.